论文部分内容阅读
美国的医学家在马里兰州贝塞斯达城宣称,他们首次在人类应用一种通过遗传把细胞活素和毒素融合在一起的嵌合物来治疗淋巴恶性疾病。这是一种由白喉毒素和白细胞介素-2融合在一起的嵌合物。据称白细胞介素-2一旦与白喉毒素融合后,白喉毒素就不再与体内的细胞结合,但却结合在具有白细胞介素-2受体的肿瘤细胞上.然后肿瘤细胞便把这种嵌合物吞噬入胞内,从而使肿瘤细胞受到白喉毒素的毒害。成人 T 细胞白血病,毛细胞白血病、慢性淋巴细胞白血病、何杰金氏病和非何杰金氏淋巴瘤等病适合试用这种嵌合物来治疗.
U.S. physicians in Bethesda, Maryland, claim they are the first to treat a lymphoid malignancy in humans using a chimera that genetically binds cytokines and toxins. This is a chimera that is fused together by diphtheria toxin and interleukin-2. Diphtheria toxin is said to no longer bind to the body’s cells once it has been fused with diphtheria toxin but binds to the tumor cells with the interleukin-2 receptor, which tumor cells then incorporate The phagocytosis of the compound into the cell causes the tumor cells to be poisoned by diphtheria toxin. Adult T-cell leukemia, hairy cell leukemia, chronic lymphocytic leukemia, Hodgkin’s disease and non-Hodgkin’s lymphoma and other diseases suitable to try this chimera to treat.